Vilobelimab

韦洛利单抗

Report date: 2025/02/08 17:30:10
First In Class

Base Information

Drug NameVilobelimab
Drug Alias NameGohibicIFX-1CaCP-29
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionComplement C5a inhibitors
TargetsComplement C5a
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsSystemic Inflammatory Response Syndrome +[12] 
Global Approved IndicationsRespiratory Distress Syndrome, Adult
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/01/13
Country/TerritoryCzechiaBelgiumBulgaria +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesInflarx Nv
China Registration ClassN/A

Develop Information

Active CompaniesPPD Development LPInflarx NvInflarx +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pyoderma GangrenosumAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[7] 
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsSystemic Inflammatory Response SyndromeCarcinoma, Squamous Cell +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG